Sunitinib Induced Thrombotic Thrombocytopenic Purpura in addition to Severe Hypothyroidism: A Case Report and Review of the Literature

Introduction. Sunitinib malate is an oral multitargeting tyrosine kinase inhibitor approved for the first line treatment of metastatic renal cell carcinoma. Sunitinib administration is associated with several adverse events including fatigue, diarrhea, skin toxicity, hypothyroidism, and cytopenia. H...

Descripción completa

Detalles Bibliográficos
Autores principales: El Dika, Imane, Mukherji, Deborah, Temraz, Sally, Assi, Rita, Shamseddine, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202279/
https://www.ncbi.nlm.nih.gov/pubmed/25349620
http://dx.doi.org/10.1155/2014/958414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202279/
https://www.ncbi.nlm.nih.gov/pubmed/25349620
http://dx.doi.org/10.1155/2014/958414

Ejemplares similares